- Conditions
- End Stage Renal Disease, Chronic Hepatitis c
- Interventions
- Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 34 Years to 44 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced May 22, 2026, 12:16 AM EDT